- ADARx Pharmaceuticals is marketing 21.875 million shares at $15 to $17 each to raise as much as $371.9 million, according to a filing made Monday with the Securities and Exchange Commission. At the top of the range the San Diego company would be valued at about $1.74 billion, with pricing expected September 24 and a Nasdaq listing under the ticker ADRX.
- AbbVie, which already has a collaboration agreement with ADARx, agreed to buy shares in a private placement at the IPO price for a stake of roughly 4.9%, capped at $100 million. AbbVie paid $335 million upfront under that collaboration in May 2025, and ADARx remains eligible for several billion dollars in option fees, milestones and tiered royalties.
- Losses are widening faster than revenue. ADARx reported a net loss of $48.4 million on collaboration revenue of $2.9 million for the six months to June 30, against a loss of $33.6 million on revenue of $208,000 in the same period last year. Three therapeutic candidates are in clinical development and two are preclinical.
- Existing holders are selling down without exiting. OrbiMed Advisors falls to 23% from 31%, LAV to 12% from 16%, chief executive Zhen Li to 10% from 13% and SR One to 8.2% from 11%, leaving a relatively thin public float of roughly 20% of the company.
What Happened?
ADARx develops small interfering RNA therapies, which target diseases at the genetic level without permanently altering a patient genome or DNA. Its candidates address eye diseases, renal disorders, obesity and Alzheimer disease. Bain Capital Life Sciences and TCGX led a $200 million Series C in 2023 that brought in BlackRock, Invus, Marshall Wace and T. Rowe Price. JPMorgan, Morgan Stanley, Toronto-Dominion, UBS and LifeSci Capital are leading the offering.
Why It Matters?
The AbbVie relationship is the whole investment case and the whole risk. Collaboration revenue is the only revenue ADARx has, AbbVie is the collaborator, AbbVie funded the company with $335 million upfront last year, and AbbVie is now anchoring the public offering by taking 4.9% at the IPO price. That is a strong validation signal, and it is also single-counterparty concentration of an unusual degree. Investors buying at $1.74 billion are underwriting one pharmaceutical company continued interest in this pipeline, and the several billion dollars in potential milestones that make the valuation defensible are contingent on decisions AbbVie alone controls. The financial trajectory deserves plain treatment. Losses grew 44% year on year to $48.4 million in a half year while revenue went from negligible to still small, which annualises to roughly $97 million of burn. Gross proceeds of $371.9 million therefore buy something close to three to four years of runway on current spending, and clinical-stage costs rise as candidates advance, so the practical figure is shorter. The float is the third consideration. Insiders retain roughly 80% after the offering, which limits supply and can produce sharp moves in both directions on modest volume, and it means early trading will say more about scarcity than about how the market values the science.
What Next?
Pricing on September 24 is the immediate event, and where it lands within or outside the $15 to $17 range is the first read on institutional appetite for clinical-stage biotech in a rising rate environment. Watch whether AbbVie takes the full $100 million permitted under the placement, since anything less would soften the validation the deal is built on. After listing, the milestones to track are clinical readouts from the three candidates in development, because with collaboration revenue this small the valuation rests entirely on pipeline progress. Any expansion or amendment of the AbbVie agreement is the most consequential single event for the shares in either direction. Lock-up expiry is the other date to mark, given that holders retaining 23%, 12%, 10% and 8.2% stakes represent substantial supply that has not yet reached the market.
Affected Tickers and Coins: ADRX, ABBV, TROW, BLK
Source: Bloomberg
